published research suggests it may detect amyloid buildup before it's evident on scans.Braunstein said the company will seek FDA approval and the agency has given it a designation that can speed review.
He said study results would be published, and he defended the decision to start selling the test now. “Should we be holding that technology back when it could have a big impact on patient care?" he asked.
WHAT OTHERS SAYDr. Eliezer Masliah, neuroscience chief at the U.S. National Institute on Aging, said the government funded some of the work leading to the test as well as other kinds of blood tests. “I would be cautious about interpreting any of these things,” he said of the company’s claims. “We’re encouraged, we’re interested, we’re.